Koichi Azuma

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.1K citations

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pharmacology +6

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo et al. · The Lancet · 2017 · 895 citations

Medicine, Randomised Phase 3, Pathology +8

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

Koichi Azuma, Keiichi Ota, Akihiko Kawahara et al. · Annals of Oncology · 2014 · 672 citations · Full text

Oncology, Medicine, Nonsmall-cell Lung Cancer +9

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 662 citations · Full text

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pathology +6

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

Haruhiro Saito, Tatsuro Fukuhara, Naoki Furuya et al. · The Lancet Oncology · 2019 · 626 citations

Interim Analysis, Oncology, Bevacizumab Versus Erlotinib +8